Merck & Co., Inc.
Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) by Quarter
Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M)
Merck Daiichi Sankyo (3 DXd ADC Oncology Programs): $100M in Q2 2026, down 88.2% from a year earlier.
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-07) ↗
Reported in Form 10-Q / 10-K Note 3/4 Collaborative Arrangements.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Daiichi Sankyo (3 DXd ADC Oncology Programs) — Current payables / liabilities to partner ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 100 | -88.2% | Form 10-Q (filed 2026-08-07) ↗ |
| Q1 2026 | Mar 31, 2026 | 85 | -89.4% | Form 10-Q (filed 2026-05-04) ↗ |
| Q4 2025 | Dec 31, 2025 | 113 | -86.2% | Form 10-Q (filed 2026-08-07) ↗ |
| Q3 2025 | Sep 30, 2025 | 869 | +7.2% | Form 10-Q (filed 2025-11-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 850 | +6.1% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 803 | -1.7% | Form 10-Q (filed 2025-05-02) ↗ |
| Q4 2024 | Dec 31, 2024 | 817 | +2.1% | Form 10-K (filed 2026-02-24) ↗ |
| Q3 2024 | Sep 30, 2024 | 811 | – | Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 801 | – | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 817 | – | Form 10-Q (filed 2024-05-03) ↗ |
| Q4 2023 | Dec 31, 2023 | 800 | – | Form 10-K (filed 2025-02-25) ↗ |
Cite this data
StockData. (2026). Merck Daiichi Sankyo (3 DXd ADC Oncology Programs) ($M), quarterly Q4 2023–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/collab-daiichisankyo-ap-cur
See every metric in the Merck KPI table. Data updated Oct 26, 2026.
See a number that looks wrong?